Xilio Therapeutics (XLO) Non-Current Deffered Revenue (2024 - 2026)

Xilio Therapeutics has disclosed Non-Current Deffered Revenue across 3 years of filings, most recently posting $16.5 million for Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $16.5 million, down 57.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.5 million (down 57.49% YoY), and the FY2025 annual result was $20.6 million, up 7.13% from the prior year.
• Non-Current Deffered Revenue came in at $16.5 million for Q1 2026 at Xilio Therapeutics, down from $20.6 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $38.7 million in Q1 2025 to a low of $8.4 million in Q3 2024.
• The 3-year median for Non-Current Deffered Revenue is $19.3 million (2024), against an average of $20.6 million.
• Across the five-year window, Non-Current Deffered Revenue soared 203.58% in 2025 and tumbled 57.49% in 2026, its largest moves.
• Xilio Therapeutics' Non-Current Deffered Revenue stood at $19.3 million in 2024, then increased by 7.13% to $20.6 million in 2025, then decreased by 20.19% to $16.5 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $16.5 million (Q1 2026), $20.6 million (Q4 2025), and $25.5 million (Q3 2025), per Business Quant data.